Results 1 to 10 of about 28,818 (194)
A Tablet Matrix with Hibiscus rosa Sinensis Leave Mucilage for Effective Treatment of Rare Lymphangioleiomyomatosis Using Sirolimus [PDF]
Trends in Pharmaceutical Sciences, 2022 Using a blend of herbal and synthetic polymers, the authors aim to extend the release of Sirolimus from the tablets. Sirolimus was used as a model drug, Hydroxy Propyl Methyl Cellulose was used as a synthetic polymer, and mucilage from Hibiscus rosa ...
Hindustan Abdul Ahad +5 more
doaj +1 more source
Frontiers in Pharmacology, 2023 The mTOR inhibitor sirolimus is prescribed to treat children with varying diseases, ranging from vascular anomalies to sporadic lymphangioleiomyomatosis to transplantation (solid organ or hematopoietic cell).
Guofang Shen +7 more
doaj +1 more source
Lupus Science and Medicine, 2022 Objective The effectiveness and safety of sirolimus for SLE treatment have been shown in some uncontrolled studies. However, a comparison of sirolimus with other classic immunosuppressants has not been reported.
Xiaofeng Zeng +15 more
doaj +1 more source
Interactions Between Sirolimus and Anti-Inflammatory Drugs: Competitive Binding for Human Serum Albumin [PDF]
Advanced Pharmaceutical Bulletin, 2016 Purpose: The aim of the present study was investigating the effects of three anti-inflammatory drugs, on Sirolimus protein biding. The binding site of Sirolimus on human serum albumin (HSA) was also determined.
Arash Khodaei +4 more
doaj +1 more source
Sirolimus induced phosphaturia is not caused by inhibition of renal apical sodium phosphate cotransporters. [PDF]
PLoS ONE, 2012 The vast majority of glomerular filtrated phosphate is reabsorbed in the proximal tubule. Posttransplant phosphaturia is common and aggravated by sirolimus immunosuppression. The cause of sirolimus induced phosphaturia however remains elusive.
Maria Haller +10 more
doaj +1 more source
Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy. [PDF]
, 2016 Preclinical models suggest that histone deacetylase (HDAC) and mammalian target of rapamycin (mTOR) inhibitors have synergistic anticancer activity. We designed a phase I study to determine the safety, maximum tolerated dose (MTD), recommended phase II ...
Falchook, Gerald S. +17 more
core +5 more sources
Journal of Research in Medical Sciences, 2023 Background: Sirolimus is a potent immunosuppressive in renal transplantation. However, its use is limited by some reported side effects. The objective of this study was to determine the side effect profile of sirolimus in renal transplant patients ...
Shahrzad Shahidi +3 more
doaj +1 more source
Sirolimus in renal transplantation [PDF]
Nephrology Dialysis Transplantation, 2007 Acute rejection episodes are now as low as 5-20% in the first year after renal transplantation; however, graft half-life has remained almost unchanged in the last decade. This statistic is mainly attributable to the side effects of immunosuppression, with loss of allografts due to the chronic allograft nephropathy that is a consequence of calcineurin ...
Vedat Schwenger +6 more
openaire +3 more sources
Bioactive Materials, 2020 Pharmacokinetic analyses were performed using 20 pigs for 120-days implantation, while one sirolimus-eluting stent was implanted into one of their coronary artery.
Shanshan Chen +8 more
doaj +1 more source
Frontiers in Pediatrics, 2022 BackgroundDespite recent developments, the role of sirolimus in the heterogeneous spectrum of vascular anomalies is yet to be defined, in terms of indication, dosage, and therapy duration, recognizing both its potential and limitations.MethodsWe ...
Anna Karastaneva +17 more
doaj +1 more source